This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
(CE/CME Podcast) Improving Outcomes in Patients With Geographic Atrophy: Epidemiology, Pathophysiology, and Imaging
MedEdicus Podcasts
25 minutes
1 year ago
(CE/CME Podcast) Improving Outcomes in Patients With Geographic Atrophy: Epidemiology, Pathophysiology, and Imaging
Activity Description and Purpose This educational activity delves into the latest clinical practices for managing geographic atrophy (GA), a severe form of dry age-related macular degeneration. Learners will gain an in-depth understanding of epidemiologic indicators, diagnostic imaging, and the pathophysiology of GA related to the complement cascade. Learners will also gain a deeper understanding of GA by reviewing a case study along with the expert presenters. Designed to enhance clinical...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
